Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...

HealthDay News — Cannabis use is associated with major adverse cardiovascular events (MACE), according to a systematic review based on real-world data published online June 17 in Heart.

Decision-making was influenced by patient values and did not vary by stage, race and ethnicity, or demographics ...

A single dose of a synthetic, proprietary formulation of psilocybin (COMP360) was found to improve symptoms in patients with treatment-resistant ...

Through August 16, 2024, the Agency has identified 13 cases worldwide of hyperthermia associated with scopolamine patches.

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The initiative, referred to as the Commissioner’s National Priority Voucher program, allows drug developers to participate in a novel FDA priority program. The program significantly shortens the FDA ...

The Food and Drug Administration (FDA) has approved Andembry ® (garadacimab-gxii) for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years ...

Largest percentage of emergency department tooth disorder visits accounted for by adults ages 25 to 34 years, White non-Hispanics ...